Alphagan P : HCP - Efficacy


	ALPHAGAN^® P 0.1% delivers proven IOP reduction when added to a PGA¹

ALPHAGAN^® P ophthalmic solution is indicated for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Important Safety Information
ALPHAGAN^® P (brimonidine tartrate ophthalmic solution) 0.1% is contraindicated in patients receiving monoamine oxidase (MAO) inhibitor therapy. Although ALPHAGAN^® P 0.1% ophthalmic solution had minimal effect on the blood pressure of patients in clinical studies, caution should be exercised in treating patients with severe cardiovascular disease. Adverse events occurring in approximately 10% to 20% of the subjects included: allergic conjunctivitis, conjunctival hyperemia, and eye pruritus.

Please click here for full Prescribing Information.

_{1. Data on file, Allergan, Inc., 2007; Day; Study MA-AP01.

Azopt is a registered trademark owned by Alcon Laboratories, Inc.}